Bevacizumab (Avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma

Dimitrios Brouzas, Antonios Charakidas, Marilita Moschos, Chryssanthi Koutsandrea, Michael Apostolopoulos, Stefanos Baltatzis1st Department of Ophthalmology, University of Athens, Athens, GreecePurpose: To establish the efficacy and safety of intravitreal bevacizumab in reducing iris and anterior ch...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dimitrios Brouzas, Antonios Charakidas, Marilita Moschos, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/b6c633c9407d42bd92ed654dde66ea31
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b6c633c9407d42bd92ed654dde66ea31
record_format	dspace
spelling	oai:doaj.org-article:b6c633c9407d42bd92ed654dde66ea312021-12-02T08:48:54ZBevacizumab (Avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma1177-54671177-5483https://doaj.org/article/b6c633c9407d42bd92ed654dde66ea312009-11-01T00:00:00Zhttp://www.dovepress.com/bevacizumab-avastinreg-for-the-management-of-anterior-chamber-neovascu-a3767https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Dimitrios Brouzas, Antonios Charakidas, Marilita Moschos, Chryssanthi Koutsandrea, Michael Apostolopoulos, Stefanos Baltatzis1st Department of Ophthalmology, University of Athens, Athens, GreecePurpose: To establish the efficacy and safety of intravitreal bevacizumab in reducing iris and anterior chamber angle neovascularization and managing neovascular glaucoma.Design: Prospective interventional case series.Patient and methods: Eleven eyes of 11 patients with iris and anterior chamber angle neovascularization with refractory intraocular pressure were treated with intravitreal injection of 1.25 mg bevacizumab (Avastin&reg;). The study group included eight males and three females aged 23 to 77 years (average, 62 years). Out of the 11 cases, five had proliferative diabetic retinopathy, of whom two had undergone vitrectomy for tractional retinal detachment and vitreous hemorrhage, and six were secondary to ischemic central retinal vein occlusion (CRVO). All patients were followed for eight to 16 months (average, 10 months).Results: Iris and anterior chamber angle neovascularization receded in all eyes after one to three injections at monthly intervals. In five eyes, neovascularization recurred during the follow-up period. The intraocular pressure normalized in one eye. Four eyes were controlled with antiglaucoma drops. A cyclodestructive procedure was required in two eyes. An Ahmet drainage valve was implanted in four eyes, including one controlled with additional antiglaucoma drops and one in which the intraocular pressure remained high while on maximum antiglaucoma medication and a cyclodestructive procedure was scheduled.Conclusions: Bevacizumab appears to be effective in reducing iris and anterior chamber angle neovascularization and is likely to extend our therapeutic options in the management of neovascular glaucoma.Keywords: bevacizumab, Avastin&reg;, iris neovascularization, anterior chamber angle neovascularization, neovascular glaucoma Dimitrios BrouzasAntonios CharakidasMarilita Moschoset alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2009, Iss default, Pp 685-688 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Dimitrios Brouzas Antonios Charakidas Marilita Moschos et al Bevacizumab (Avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma
description	Dimitrios Brouzas, Antonios Charakidas, Marilita Moschos, Chryssanthi Koutsandrea, Michael Apostolopoulos, Stefanos Baltatzis1st Department of Ophthalmology, University of Athens, Athens, GreecePurpose: To establish the efficacy and safety of intravitreal bevacizumab in reducing iris and anterior chamber angle neovascularization and managing neovascular glaucoma.Design: Prospective interventional case series.Patient and methods: Eleven eyes of 11 patients with iris and anterior chamber angle neovascularization with refractory intraocular pressure were treated with intravitreal injection of 1.25 mg bevacizumab (Avastin&reg;). The study group included eight males and three females aged 23 to 77 years (average, 62 years). Out of the 11 cases, five had proliferative diabetic retinopathy, of whom two had undergone vitrectomy for tractional retinal detachment and vitreous hemorrhage, and six were secondary to ischemic central retinal vein occlusion (CRVO). All patients were followed for eight to 16 months (average, 10 months).Results: Iris and anterior chamber angle neovascularization receded in all eyes after one to three injections at monthly intervals. In five eyes, neovascularization recurred during the follow-up period. The intraocular pressure normalized in one eye. Four eyes were controlled with antiglaucoma drops. A cyclodestructive procedure was required in two eyes. An Ahmet drainage valve was implanted in four eyes, including one controlled with additional antiglaucoma drops and one in which the intraocular pressure remained high while on maximum antiglaucoma medication and a cyclodestructive procedure was scheduled.Conclusions: Bevacizumab appears to be effective in reducing iris and anterior chamber angle neovascularization and is likely to extend our therapeutic options in the management of neovascular glaucoma.Keywords: bevacizumab, Avastin&reg;, iris neovascularization, anterior chamber angle neovascularization, neovascular glaucoma
format	article
author	Dimitrios Brouzas Antonios Charakidas Marilita Moschos et al
author_facet	Dimitrios Brouzas Antonios Charakidas Marilita Moschos et al
author_sort	Dimitrios Brouzas
title	Bevacizumab (Avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma
title_short	Bevacizumab (Avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma
title_full	Bevacizumab (Avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma
title_fullStr	Bevacizumab (Avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma
title_full_unstemmed	Bevacizumab (Avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma
title_sort	bevacizumab (avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/b6c633c9407d42bd92ed654dde66ea31
work_keys_str_mv	AT dimitriosbrouzas bevacizumabavastinampregforthemanagementofanteriorchamberneovascularizationandneovascularglaucoma AT antonioscharakidas bevacizumabavastinampregforthemanagementofanteriorchamberneovascularizationandneovascularglaucoma AT marilitamoschos bevacizumabavastinampregforthemanagementofanteriorchamberneovascularizationandneovascularglaucoma AT etal bevacizumabavastinampregforthemanagementofanteriorchamberneovascularizationandneovascularglaucoma
_version_	1718398385608720384

Bevacizumab (Avastin&amp;reg;) for the management of anterior chamber neovascularization and neovascular glaucoma

Ejemplares similares

Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma